Home pageSGEN • BMV
add
Seagen
Chiusura precedente
3.711,48 $
Intervallo annuale
3.711,48 $ - 3.711,48 $
Cap di mercato
43,15 Mrd USD
Rapporto P/E
-
Dividendo/Prezzo
-
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | set 2023info | Variazione Y/Y |
---|---|---|
Entrate | 648,65 Mln | 27,11% |
Spese di gestione | 262,69 Mln | 24,86% |
Utile netto | -215,79 Mln | -13,09% |
Margine di profitto netto | -33,27 | 11,02% |
Utili per azione | -1,15 | -11,65% |
EBITDA | -209,33 Mln | -19,47% |
Aliquota fiscale effettiva | 0,26% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | set 2023info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 1,24 Mrd | -29,86% |
Totale attivo | 3,63 Mrd | 0,42% |
Totale passivo | 1,08 Mrd | 35,94% |
Patrimonio netto totale | 2,55 Mrd | — |
Azioni in circolazione | 188,66 Mln | — |
Prezzo/valore contabile | 274,52 | — |
Redditività dell'attivo | -16,01% | — |
Rendimento sul capitale | -21,12% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | set 2023info | Variazione Y/Y |
---|---|---|
Utile netto | -215,79 Mln | -13,09% |
Liquidità di esercizio | -35,82 Mln | 58,21% |
Contanti da investimenti | 142,49 Mln | 119,31% |
Contanti da finanziamenti | 15,52 Mln | -15,59% |
Flusso di cassa netto | 119,90 Mln | 1.958,05% |
Flusso di cassa libero | 71,52 Mln | 1.141,10% |
Informazioni
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Fondazione
15 lug 1997
Sito web
Dipendenti
3.256